SII seeks emergency use approval for Covovax Covid vaccine for 12-17 age group
Covid-19 vaccine Covovax for the 12 to 17 year age group, reported PTI, quoting sources, on Monday. "We are submitting our application along with documents for grant of permission for restricted use in an emergency situation for Covovax vaccine in children aged 12 to 17 years in addition to approved age of individuals 18 years and older," an official source was quoted as saying by the news agency.
Further, as per the report, Prakash Kumar Singh, the director of government and regulatory affairs at SII, has stated in the company's application that data from two studies on about 2,707 individuals aged 12 to 17 years show Covovax is highly efficacious, immunogenic, safe and well-tolerated. "In line with the philosophy of our CEO Dr Adar C Poonawalla, we are sure that Covovax will play an important role in protecting the children of our country and the world against Covid-19 and will keep our national flag flying high globally," Singh reportedly said.
The government has not yet decided on vaccinating those aged below 15. India has been using Bharat Biotech's Covaxin to vaccinate adolescents between 15 and 18 years.
The health ministry had recently said the additional need for vaccination and inclusion of population for inoculation is examined constantly.
United States
|
Cases: 46 252 513
Deaths: 750 423
Recovered: 0
|
India
|
Cases: 34 321 025
Deaths: 459 652
Recovered: 0
|
Brazil
|
Cases: 21 835 785
Deaths: 608 235
Recovered: 0
|
United Kingdom
|
Cases: 9 215 683
Deaths: 141 607
Recovered: 0
|
Russia
|
Cases: 8 494 589
Deaths: 237 619
Recovered: 0
|